U. Autres-liens, 181 8.1. Professionnels de, Congres internationaux, p.183

S. De, G. Bogaard, H. Condliffe, R. Frantz, R. Khanna et al., Definitions and diagnosis of pulmonary hypertension, J Am Coll Cardiol, vol.62, pp.42-50, 2013.

G. Kovacs, A. Berghold, S. Scheidl, and H. Olschewski, Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review, European Respiratory Journal, vol.34, issue.4, pp.888-894, 2009.
DOI : 10.1183/09031936.00145608

G. Simonneau, N. Galie, L. Rubin, D. Langleben, W. Seeger et al., Clinical classification of pulmonary hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.5-12, 2004.
DOI : 10.1016/j.jacc.2004.02.037

H. Farber and J. Loscalzo, Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.16, pp.1655-1665, 2004.
DOI : 10.1056/NEJMra035488

G. Simonneau, I. Robbins, M. Beghetti, R. Channick, M. Delcroix et al., Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, 2009.

W. Mclaughlin, K. Presberg, R. Doyle, S. Abman, D. Mccrory et al., Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004.
DOI : 10.1378/chest.126.1_suppl.78S

J. Gibbs, C. Broberg, and M. Gatzoulis, Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities, International Journal of Cardiology, vol.97, pp.7-10, 2004.
DOI : 10.1016/j.ijcard.2004.08.003

M. Opravil, M. Pechere, and R. Speich, HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study., American Journal of Respiratory and Critical Care Medicine, vol.155, issue.3, pp.990-995, 1997.
DOI : 10.1164/ajrccm.155.3.9117037

N. Galie, A. Torbicki, and R. Barst, Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J, vol.25, pp.2243-2278, 2004.

M. Humbert, O. Sitbon, and A. Chaouat, Pulmonary Arterial Hypertension in France, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.9, pp.1023-1030, 2006.
DOI : 10.1164/rccm.200510-1668OC

L. Abenhaim, Y. Moride, and F. Brenot, Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension, New England Journal of Medicine, vol.335, issue.9, pp.609-616, 1996.
DOI : 10.1056/NEJM199608293350901

S. Rich, D. Dantzker, and S. Ayres, Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.107, issue.2, pp.216-223, 1987.
DOI : 10.7326/0003-4819-107-2-216

L. Rubin, Primary Pulmonary Hypertension, New England Journal of Medicine, vol.336, issue.2, pp.111-117, 1997.
DOI : 10.1056/NEJM199701093360207

J. Newman, L. Wheeler, and K. Lane, Mutation in the Gene for Bone Morphogenetic Protein Receptor II as a Cause of Primary Pulmonary Hypertension in a Large Kindred, New England Journal of Medicine, vol.345, issue.5, pp.319-324, 2001.
DOI : 10.1056/NEJM200108023450502

D. Dresdale, M. R. Schultz, and M. , Recent Studies in Primary Pulmonary Hypertension Including Pharmacodynamic Observations on Pulmonary Vascular Resistance, Bull N Y Acad Med, vol.30, pp.195-207, 1954.

Z. Deng, J. Morse, and S. Stager, Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor???II Gene, The American Journal of Human Genetics, vol.67, issue.3, pp.737-781, 2000.
DOI : 10.1086/303059

J. Loyd, M. Butler, T. Foroud, P. Conneally, J. Phillips et al., Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.152, issue.1, pp.93-100, 1995.
DOI : 10.1164/ajrccm.152.1.7599869

B. Sztrymf, A. Yaici, B. Girerd, and H. M. , Genes and Pulmonary Arterial Hypertension, Respiration, vol.102, issue.2, pp.123-155, 2007.
DOI : 10.1161/01.CIR.102.16.2005

J. Loyd, M. Butler, T. Foroud, P. Conneally, J. Phillips et al., Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.152, issue.1, pp.93-97, 1995.
DOI : 10.1164/ajrccm.152.1.7599869

R. Trembath, Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.175, 2001.
DOI : 10.1016/S1053-2498(00)00352-1

S. Eddahibi, M. Humbert, and E. Fadel, Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension, Journal of Clinical Investigation, vol.108, issue.8, pp.1141-1150, 2001.
DOI : 10.1172/JCI200112805

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC209526/pdf

M. Humbert and R. Trembath, Genetics of pulmonary hypertension: from bench to bedside, European Respiratory Journal, vol.20, issue.3, pp.741-749, 2002.
DOI : 10.1183/09031936.02.02702002

H. Farber and J. Loscalzo, Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.16, pp.1655-1665, 2004.
DOI : 10.1056/NEJMra035488

B. Christman, C. Mcpherson, and J. Newman, An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.70-75, 1992.
DOI : 10.1056/NEJM199207093270202

A. Giaid and D. Saleh, Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.333, issue.4, pp.214-221, 1995.
DOI : 10.1056/NEJM199507273330403

A. Giaid, M. Yanagisawa, and D. Langleben, Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.328, issue.24, pp.1732-1739, 1993.
DOI : 10.1056/NEJM199306173282402

L. Spieker, G. Noll, F. Ruschitzka, and L. , Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?, Journal of the American College of Cardiology, vol.37, issue.6, pp.1493-1505, 2001.
DOI : 10.1016/S0735-1097(01)01210-4

P. Herve, J. Launay, and M. Scrobohaci, Increased plasma serotonin in primary pulmonary hypertension, The American Journal of Medicine, vol.99, issue.3, pp.249-254, 1995.
DOI : 10.1016/S0002-9343(99)80156-9

V. Petkov, W. Mosgoeller, and R. Ziesche, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, Journal of Clinical Investigation, vol.111, issue.9, pp.1339-1346, 2003.
DOI : 10.1172/JCI17500

Y. Xi, J. Wang, M. Juhaszova, S. Gaine, and U. Rubin, Attenuated K+ channel gene transcription in primary pulmonary hypertension, Lancet, vol.351, pp.726-727, 1998.

Y. Zhao, J. Wang, U. Rubin, and Y. Xi, Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery, Am J Physiol, vol.272, pp.904-912, 1997.

M. Kakishita, T. Nishikimi, and Y. Okano, Increased plasma levels of adrenomedullin in patients with pulmonary hypertension, Clinical Science, vol.96, issue.1, pp.33-39, 1999.
DOI : 10.1042/cs0960033

R. Tuder, M. Chacon, and L. Alger, Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis, The Journal of Pathology, vol.88, issue.3, pp.367-374, 2001.
DOI : 10.1161/01.RES.88.1.e2

N. Galie, A. Torbicki, and R. Barst, Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J, vol.25, pp.2243-2278, 2004.

C. Elliot and D. Kiely, Pulmonary hypertension, Continuing Education in Anaesthesia, Critical Care & Pain, vol.6, issue.1, pp.17-22, 2006.
DOI : 10.1093/bjaceaccp/mki061

G. Ahearn, V. Tapson, A. Rebeiz, J. Greenfield, and . Jr, Electrocardiography to Define Clinical Status in Primary Pulmonary Hypertension and Pulmonary Arterial Hypertension Secondary to Collagen Vascular Disease, Chest, vol.122, issue.2, pp.524-527, 2002.
DOI : 10.1378/chest.122.2.524

N. Galie, A. Manes, and A. Branzi, Evaluation of pulmonary arterial hypertension, Current Opinion in Cardiology, vol.19, issue.6, pp.575-581, 2004.
DOI : 10.1097/01.hco.0000142066.14966.85

R. Barst, M. Mcgoon, and A. Torbicki, Diagnosis and differential assessment of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.405-452, 2004.
DOI : 10.1016/j.jacc.2004.02.032

J. Gibbs, Making a diagnosis in PAH, European Respiratory Review, vol.16, issue.102, pp.8-12, 2007.
DOI : 10.1183/09059180.00010203

URL : http://err.ersjournals.com/content/errev/16/102/8.full.pdf

N. Selimovic, B. Rundqvist, and C. Bergh, Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension, The Journal of Heart and Lung Transplantation, vol.26, issue.9, pp.927-934, 2007.
DOI : 10.1016/j.healun.2007.06.008

M. Escribano, P. , G. Sanchez, M. Diaz-de-atauri, and M. , Lung function testing in patients with pulmonary arterial hypertension, Arch Bronconeumol, vol.41, pp.380-384, 2005.

A. Williams, ABC of oxygen: Assessing and interpreting arterial blood gases and acid-base balance, BMJ, vol.317, issue.7167, p.1213, 1998.
DOI : 10.1136/bmj.317.7167.1213

M. Hoeper, M. Pletz, H. Golpon, and T. Welte, Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.29, issue.5, p.134506, 2007.
DOI : 10.1183/09031936.00134506

O. Worsley, H. Palevsky, and A. Alavi, Ventilation-Perfusion lung scanning in the evaluation of pulmonary hypertension, J Nuclear Med, vol.35, pp.793-796, 1994.

P. Enright, The six minute walking test, Respir Care, vol.48, pp.783-785, 2003.

S. Miyamoto, N. Nagaya, and . Satoh, Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.2, pp.487-492, 2000.
DOI : 10.1164/ajrccm.161.2.9906015

M. Hoeper, R. Oudiz, and A. Peacock, End points and clinical trial designs in pulmonary arterial hypertension. Clinical and regulatory perspective, J Am Coll Cardiol, vol.43, pp.485-555, 2004.

S. Rich, D. Dantzker, and S. Ayres, Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.107, issue.2, pp.216-223, 1987.
DOI : 10.7326/0003-4819-107-2-216

K. Muralidhar, Central venous pressure and pulmonary capillary wedge pressure monitoring, Indian J Anaesth, vol.46, pp.298-303, 2002.

O. Sitbon, M. Humbert, and X. Jaïs, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, vol.1, issue.1, pp.3105-3111, 2005.
DOI : 10.1161/circulationaha.104.488486

URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf

W. Mclaughlin, K. Presberg, and R. Doyle, Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004.
DOI : 10.1378/chest.126.1_suppl.78S

D. Badesh, S. Abman, and G. Ahearn, Medical therapy for pulmonary arterial hypertension, Chest, vol.126, issue.1, pp.355-62, 2004.

F. Brenot, Primary Pulmonary Hypertension, Chest, vol.105, issue.2, pp.33-36, 1994.
DOI : 10.1378/chest.105.2_Supplement.33S

D. Alonzo, G. Barst, R. Ayres, S. Bergofsky, E. Brundage et al., Survival in Patients with Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.115, issue.5, pp.343-349, 1991.
DOI : 10.7326/0003-4819-115-5-343

S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki et al., Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.2, pp.487-492, 2000.
DOI : 10.1164/ajrccm.161.2.9906015

G. Paciocco, F. Martinez, E. Bossone, E. Pielsticker, B. Gillespie et al., Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension, European Respiratory Journal, vol.17, issue.4, pp.647-652, 2001.
DOI : 10.1183/09031936.01.17406470

R. Wensel, C. Opitz, S. Anker, J. Winkler, G. Hoffken et al., Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing, Circulation, vol.106, issue.3, pp.319-324, 2002.
DOI : 10.1161/01.CIR.0000022687.18568.2A

O. Sitbon, M. Humbert, X. Jaïs, V. Loos, A. Hamid et al., Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.488486

URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf

R. Raymond, A. Hinderliter, P. Willis, R. D. Caldwell, E. Williams et al., Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.39, issue.7, pp.1214-1219, 2002.
DOI : 10.1016/S0735-1097(02)01744-8

T. Yeo, K. Dujardin, C. Tei, D. Mahoney, M. Mcgoon et al., Value of a Doppler-Derived Index Combining Systolic and Diastolic Time Intervals in Predicting Outcome in Primary Pulmonary Hypertension, The American Journal of Cardiology, vol.81, issue.9, pp.1157-1161, 1998.
DOI : 10.1016/S0002-9149(98)00140-4

P. Forfia, M. Fisher, S. Mathai, T. Housten-harris, A. Hemnes et al., Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.9, pp.1034-1041, 2006.
DOI : 10.1164/rccm.200604-547OC

URL : http://intl-ajrccm.atsjournals.org/content/174/9/1034.full.pdf

N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani et al., Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension, Circulation, vol.102, issue.8, pp.865-870, 2000.
DOI : 10.1161/01.CIR.102.8.865

R. Souza, C. Jardi, J. C. Fernande, C. , S. Lap et al., NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension, Respiratory Medicine, vol.101, issue.1, pp.69-75, 2007.
DOI : 10.1016/j.rmed.2006.04.014

C. Rubens, R. Ewert, M. Halank, R. Wensel, H. Orzechowski et al., Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension, Chest, vol.120, issue.5, pp.1562-1569, 2001.
DOI : 10.1378/chest.120.5.1562

N. Nagaya, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki et al., Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.160, issue.2, pp.487-492, 1999.
DOI : 10.1164/ajrccm.160.2.9812078

A. Torbicki, M. Kurzyna, P. Kuca, A. Fijalkowska, J. Sikora et al., Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension, Circulation, vol.108, issue.7, pp.844-848, 2003.
DOI : 10.1161/01.CIR.0000084544.54513.E2

O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia et al., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002.
DOI : 10.1016/S0735-1097(02)02012-0

URL : https://doi.org/10.1016/s0735-1097(02)02012-0

V. Mclaughlin, A. Shillington, and S. Rich, Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy, Circulation, vol.106, issue.12, pp.1477-1482, 2002.
DOI : 10.1161/01.CIR.0000029100.82385.58

S. Provencher, O. Sitbon, M. Humbert, S. Cabral, X. Jaïs et al., Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension, European Heart Journal, vol.27, issue.5, pp.589-595, 2006.
DOI : 10.1093/eurheartj/ehi728

S. Provencher, X. Jaïs, and A. Yaici, Clinical Challenges in Pulmonary Hypertension, Chest, vol.128, issue.6, pp.622-628, 2005.
DOI : 10.1378/chest.128.6_suppl.622S

G. Simonneau, N. Galie, and M. Hoeper, Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in WHO Class II pulmonary arterial hypertension (PAH) patients: EARLY study results, 2007.

M. Humbert, O. Sitbon, and G. Simonneau, Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.14, pp.1425-1436, 2004.
DOI : 10.1056/NEJMra040291

URL : https://hal.archives-ouvertes.fr/hal-01455600

D. Alonzo, G. Barst, R. Ayers, and S. , Survival in Patients with Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.115, issue.5, pp.343-349, 1991.
DOI : 10.7326/0003-4819-115-5-343

M. Hoeper, R. Oudiz, and A. Peacock, End points and clinical trial designs in pulmonary arterial hypertension. Clinical and regulatory perspectives, JAm Coll Cardiol, vol.43, pp.485-555, 2004.

S. Rich and B. Brundage, High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy, Circulation, vol.76, issue.1, pp.135-141, 1987.
DOI : 10.1161/01.CIR.76.1.135

S. Rich, E. Kaufmann, and P. Levy, The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.76-81, 1992.
DOI : 10.1056/NEJM199207093270203

O. Sitbon, M. Humbert, J. Jagot, . Taraveila-0, M. Fartoukh et al., Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension, European Respiratory Journal, vol.12, issue.2, pp.265-270, 1998.
DOI : 10.1183/09031936.98.12020265

O. Sitbon, M. Humbert, X. Jaïs, V. Loos, A. Hamid et al., Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.488486

URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf

S. Rich, E. Kaufmann, and P. Levy, The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.76-81, 1992.
DOI : 10.1056/NEJM199207093270203

O. Sitbon, M. Humbert, X. Jaïs, V. Ioos, A. Hamid et al., Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3111, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.488486

URL : http://circ.ahajournals.org/content/circulationaha/111/23/3105.full.pdf

R. Naeije and J. Vachiery, MEDICAL THERAPY OF PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.517-527, 2001.
DOI : 10.1016/S0272-5231(05)70288-4

R. Channick and I. Williamson, Diagnosis and treatment of pulmonary arterial hypertension, Cardiology Clinics, vol.22, issue.3, pp.441-452, 2004.
DOI : 10.1016/j.ccl.2004.04.004

V. Fuster, P. Steele, W. Edwards, B. Gersh, M. Mcgoon et al., Primary pulmonary hypertension: natural history and the importance of thrombosis, Circulation, vol.70, issue.4, pp.580-587, 1984.
DOI : 10.1161/01.CIR.70.4.580

R. Channick, O. Sitbon, and R. Barst, Endothelin receptor antagonists in pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.62-67, 2004.
DOI : 10.1016/j.jacc.2004.02.042

L. Rubin, D. Badesch, and R. Barst, Bosentan Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.346, issue.12, pp.896-903, 2002.
DOI : 10.1056/NEJMoa012212

R. Channick, G. Simonneau, O. Sitbon, I. Robbins, A. Frost et al., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study, The Lancet, vol.358, issue.9288, pp.1119-1123, 2001.
DOI : 10.1016/S0140-6736(01)06250-X

L. Rubin, D. Badesch, R. Barst, N. Galie, C. Black et al., Bosentan Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.346, issue.12, pp.896-903, 2002.
DOI : 10.1056/NEJMoa012212

M. Humbert, R. Barst, I. Robbins, R. Channick, N. Galie et al., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, European Respiratory Journal, vol.24, issue.3, pp.353-359, 2004.
DOI : 10.1183/09031936.04.00028404

N. Galie, L. Rubin, M. Hoeper, P. Jansa, H. Hiti et al., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial, The Lancet, vol.371, issue.9630, pp.2093-2100, 2008.
DOI : 10.1016/S0140-6736(08)60919-8

N. Galie, M. Beghetti, M. Gatzoulis, J. Granton, R. Berger et al., Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study, Circulation, vol.114, issue.1, pp.48-54, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.630715

R. Barst and L. 0. , Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan, Journal of the American College of Cardiology, vol.47, issue.10, pp.2049-2056, 2006.
DOI : 10.1016/j.jacc.2006.01.057

T. Pulido, I. Adzerikho, R. Channick, M. Delcroix, N. Galie et al., Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.369, issue.9, pp.809-818, 2013.
DOI : 10.1056/NEJMoa1213917

N. Galie, B. Brundage, H. Ghofrani, R. Oudiz, G. Simonneau et al., Tadalafil Therapy for Pulmonary Arterial Hypertension, Circulation, vol.119, issue.22, pp.2894-2903, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.839274

URL : http://circ.ahajournals.org/content/circulationaha/119/22/2894.full.pdf

Z. Jing, Z. Yu, J. Shen, B. Wu, K. Xu et al., Vardenafil in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.12, pp.1723-1729, 2011.
DOI : 10.1164/rccm.201101-0093OC

A. Giaid and D. Saleh, Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.333, issue.4, pp.214-221, 1995.
DOI : 10.1056/NEJM199507273330403

H. Ghofrani, N. Galie, F. Grimminger, E. Grunig, M. Humbert et al., Riociguat for the Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.369, issue.4, pp.330-340, 2013.
DOI : 10.1056/NEJMoa1209655

N. Galie, K. Muller, A. Scalise, and E. Grunig, PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension, European Respiratory Journal, vol.45, issue.5, pp.1314-1322, 2015.
DOI : 10.1183/09031936.00105914

N. Galie, M. Humbert, and J. Vachiery, Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial, Journal of the American College of Cardiology, vol.39, issue.9, pp.1496-502, 2002.
DOI : 10.1016/S0735-1097(02)01786-2

R. Barst, M. Mcgoon, and V. Mclaughlin, Beraprost therapy for pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.41, issue.12, pp.2119-2144, 2003.
DOI : 10.1016/S0735-1097(03)00463-7

URL : https://doi.org/10.1016/s0735-1097(03)00463-7

L. Rubin, J. Mendoza, M. Hood, M. Mcgoon, R. Barst et al., Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol), Annals of Internal Medicine, vol.112, issue.7, pp.485-491, 1990.
DOI : 10.7326/0003-4819-112-7-485

R. Barst, L. Rubin, W. Long, M. Mcgoon, S. Rich et al., A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension, New England Journal of Medicine, vol.334, issue.5, pp.296-302, 1996.
DOI : 10.1056/NEJM199602013340504

D. Badesch, V. Tapson, M. Mcgoon, B. Brundage, L. Rubin et al., Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, Annals of Internal Medicine, vol.132, issue.6, pp.425-434, 2000.
DOI : 10.7326/0003-4819-132-6-200003210-00002

A. Doran, D. Ivy, R. Barst, N. Hill, S. Murali et al., Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension, International Journal of Clinical Practice, vol.60, issue.Suppl., pp.5-9, 2008.
DOI : 10.1111/j.1742-1241.2008.01811.x

O. Sitbon, M. Delcroix, E. Bergot, A. Boonstra, J. Granton et al., EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension, American Heart Journal, vol.167, issue.2, pp.210-217, 2014.
DOI : 10.1016/j.ahj.2013.08.007

G. Simonneau, R. Barst, N. Galie, R. Naeije, S. Rich et al., Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.6, pp.800-804, 2002.
DOI : 10.1164/ajrccm.165.6.2106079

H. Olschewski, G. Simonneau, and N. Galie, Inhaled Iloprost for Severe Pulmonary Hypertension, New England Journal of Medicine, vol.347, issue.5, pp.322-329, 2002.
DOI : 10.1056/NEJMoa020204

H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije et al., Inhaled Iloprost for Severe Pulmonary Hypertension, New England Journal of Medicine, vol.347, issue.5, pp.322-329, 2002.
DOI : 10.1056/NEJMoa020204

V. Mclaughlin, R. Oudiz, A. Frost, V. Tapson, S. Murali et al., Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.11, pp.1257-1263, 2006.
DOI : 10.1164/rccm.200603-358OC

M. Hoeper, H. Leuchte, M. Halank, H. Wilkens, F. Meyer et al., Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.28, issue.4, pp.691-694, 2006.
DOI : 10.1183/09031936.06.00057906

T. Higenbottam, A. Butt, A. Mcmahon, R. Westerbeck, and L. Sharples, Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension, Heart, vol.80, issue.2, pp.151-155, 1998.
DOI : 10.1136/hrt.80.2.151

N. Galie and A. Manes, New Treatment Strategies for Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.12, pp.1101-1102, 2013.
DOI : 10.1016/j.jacc.2013.06.032

S. Chen, F. Zhang, J. Xu, D. Xie, L. Zhou et al., Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.12, pp.1092-1100, 2013.
DOI : 10.1016/j.jacc.2013.05.075

URL : https://doi.org/10.1016/j.jacc.2013.05.075

M. Hoeper, I. Markevych, and T. Spiekerkotter, Goal-oriented treatment and combination therapy for pulmonary arterial hypertension, European Respiratory Journal, vol.26, issue.5, pp.858-863, 2005.
DOI : 10.1183/09031936.05.00075305

URL : http://erj.ersjournals.com/content/erj/26/5/858.full.pdf

N. Galiè, Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.373, issue.9, pp.834-844, 2015.
DOI : 10.1056/NEJMoa1413687

D. Kerstein, P. Levy, D. Hsu, A. Hordof, W. Gersony et al., Blade Balloon Atrial Septostomy in Patients With Severe Primary Pulmonary Hypertension, Circulation, vol.91, issue.7, pp.2028-2035, 1995.
DOI : 10.1161/01.CIR.91.7.2028

A. Rothman, M. Sklansky, V. Lucas, I. Kashani, R. Shaughnessy et al., Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension, The American Journal of Cardiology, vol.84, issue.6, pp.682-686, 1999.
DOI : 10.1016/S0002-9149(99)00416-6

L. Rubin, Introduction, Chest, vol.126, issue.1, pp.7-10, 2004.
DOI : 10.1378/chest.126.1_suppl.7S

URL : https://hal.archives-ouvertes.fr/hal-00989924

J. Sandoval, A. Rothman, and T. Pulido, ATRIAL SEPTOSTOMY FOR PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.547-560, 2001.
DOI : 10.1016/S0272-5231(05)70291-4

A. Roskovec, P. Motanes, and C. Oakley, Factors that influence the outcome of primary pulmonary hypertension., Heart, vol.55, issue.5, pp.449-458, 1986.
DOI : 10.1136/hrt.55.5.449

S. Levine, W. Gibbons, C. Bryan, A. Walling, R. Brown et al., Single Lung Transplantation for Primary Pulmonary Hypertension, Chest, vol.98, issue.5, pp.1107-1115, 1990.
DOI : 10.1378/chest.98.5.1107

URL : http://publications.chestnet.org//pdfAccess.ashx?url=%2Fdata%2FJournals%2FCHEST%2F21620%2F1107.pdf

E. Pielsticker, H. Martinez, and M. Rubenfire, Lung and heart-lung transplant practice patterns in pulmonary hypertension centers, The Journal of Heart and Lung Transplantation, vol.20, issue.12, pp.1297-1304, 2001.
DOI : 10.1016/S1053-2498(01)00348-5

E. Mendeloff, B. Meyers, T. Sundt, T. Guthrie, S. Sweet et al., Lung transplantation for pulmonary vascular disease, The Annals of Thoracic Surgery, vol.73, issue.1, pp.209-217, 2002.
DOI : 10.1016/S0003-4975(01)03082-X

B. Reitz, J. Wallwork, S. Hunt, I. Pennock, M. Billingham et al., Heart-Lung Transplantation, New England Journal of Medicine, vol.306, issue.10, pp.557-564, 1982.
DOI : 10.1056/NEJM198203113061001

J. Hosenpud, L. Bennett, B. Keck, M. Boucek, and R. Novick, The registry of the international society for heart and lung transplantation: eighteenth official report???2001, The Journal of Heart and Lung Transplantation, vol.20, issue.8, pp.805-815, 2001.
DOI : 10.1016/S1053-2498(01)00323-0

L. J. Rubin, Pulmonary Arterial Hypertension, Proceedings of the American Thoracic Society, vol.3, issue.1, pp.111-115, 2006.
DOI : 10.1513/pats.200510-112JH

O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia et al., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002.
DOI : 10.1016/S0735-1097(02)02012-0

URL : https://doi.org/10.1016/s0735-1097(02)02012-0

N. Nickel, H. Golpon, M. Greer, L. Knudsen, K. Olsson et al., The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.39, issue.3, pp.589-596, 2012.
DOI : 10.1183/09031936.00092311

R. Barst, L. Chung, R. Zamanian, M. Turner, and M. Mcgoon, Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry, Chest, vol.144, issue.1, pp.160-168, 2013.
DOI : 10.1378/chest.12-2417

Y. Shimada, M. Shiota, R. Siegel, and T. Shiota, Accuracy of Right Ventricular Volumes and Function Determined by Three-Dimensional Echocardiography in Comparison with Magnetic Resonance Imaging: A??Meta-Analysis Study, Journal of the American Society of Echocardiography, vol.23, issue.9, pp.943-953, 2010.
DOI : 10.1016/j.echo.2010.06.029

E. Grunig, H. Tiede, E. Enyimayew, N. Ehlken, H. Seyfarth et al., Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension, Circulation, vol.128, issue.18, pp.2005-2015, 2013.
DOI : 10.1161/CIRCULATIONAHA.113.001573

G. Savarese, S. Paolillo, P. Costanzo, D. Amore, C. Cecere et al., Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?, Journal of the American College of Cardiology, vol.60, issue.13, pp.1192-1201, 2012.
DOI : 10.1016/j.jacc.2012.01.083

N. Gabler, B. French, B. Strom, H. Palevsky, D. Taichman et al., Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials, Circulation, vol.126, issue.3, pp.349-356, 2012.
DOI : 10.1161/CIRCULATIONAHA.112.105890

J. Fritz, C. Blair, R. Oudiz, C. Dufton, H. Olschewski et al., Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension, Chest, vol.143, issue.2, pp.315-323, 2013.
DOI : 10.1378/chest.12-0270

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694187/pdf

R. Wensel, D. Francis, F. Meyer, C. Opitz, L. Bruch et al., Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension, International Journal of Cardiology, vol.167, issue.4, pp.1193-1198, 2013.
DOI : 10.1016/j.ijcard.2012.03.135

S. Pullamsetti, L. Kiss, H. Ghofrani, R. Voswinckel, P. Haredza et al., Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension, FASEB J, vol.19, pp.1175-1177, 2005.

J. Kielstein, S. Bode-boger, G. Hesse, J. Martens-lobenhoffer, A. Takacs et al., Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, issue.7, pp.1414-1418, 2005.
DOI : 10.1161/01.ATV.0000168414.06853.f0

URL : http://atvb.ahajournals.org/content/atvbaha/25/7/1414.full.pdf

J. Kielstein, B. Impraim, S. Simmel, S. Bode-boger, D. Tsikas et al., Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans, Circulation, vol.109, issue.2, pp.172-177, 2004.
DOI : 10.1161/01.CIR.0000105764.22626.B1

S. Kawut, E. Horn, K. Berekashvili, A. Widlitz, E. Rosenzweig et al., von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension, Chest, vol.128, issue.4, pp.2355-2362, 2005.
DOI : 10.1378/chest.128.4.2355

P. Kumpers, N. Nickel, A. Lukasz, H. Golpon, V. Westerkamp et al., Circulating angiopoietins in idiopathic pulmonary arterial hypertension, European Heart Journal, vol.31, issue.18, pp.2291-2300, 2010.
DOI : 10.1093/eurheartj/ehq226

C. Rubens, R. Ewert, M. Halank, R. Wensel, H. Orzechowski et al., Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension, Chest, vol.120, issue.5, pp.1562-1569, 2001.
DOI : 10.1378/chest.120.5.1562

R. Quarck, T. Nawrot, B. Meyns, and M. Delcroix, C-Reactive Protein, Journal of the American College of Cardiology, vol.53, issue.14, pp.1211-1218, 2009.
DOI : 10.1016/j.jacc.2008.12.038

K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-gasselin, F. Capel et al., C Chemokine Fractalkine in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.10, pp.1419-1425, 2002.
DOI : 10.1164/rccm.2106007

P. Dorfmuller, V. Zarka, I. Durand-gasselin, G. Monti, K. Balabanian et al., Chemokine RANTES in Severe Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.4, pp.534-539, 2002.
DOI : 10.1164/ajrccm.165.4.2012112

M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier et al., Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.151, issue.5, pp.1628-1631, 1995.
DOI : 10.1164/ajrccm.151.5.7735624

N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani et al., Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension, Circulation, vol.102, issue.8, pp.865-870, 2000.
DOI : 10.1161/01.CIR.102.8.865

N. Nagaya, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki et al., Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.160, issue.2, pp.487-492, 1999.
DOI : 10.1164/ajrccm.160.2.9812078

J. Lorenzen, N. Nickel, R. Kramer, H. Golpon, V. Westerkamp et al., Osteopontin in Patients With Idiopathic Pulmonary Hypertension, Chest, vol.139, issue.5, pp.1010-1017, 2011.
DOI : 10.1378/chest.10-1146

G. Warwick, P. Thomas, and D. Yates, Biomarkers in pulmonary hypertension, European Respiratory Journal, vol.32, issue.2, pp.503-512, 2008.
DOI : 10.1183/09031936.00160307

N. Nickel, H. Golpon, M. Greer, L. Knudsen, K. Olsson et al., The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.39, issue.3, pp.589-596, 2012.
DOI : 10.1183/09031936.00092311

G. Warwick, P. Thomas, and D. Yates, Biomarkers in pulmonary hypertension, European Respiratory Journal, vol.32, issue.2, pp.503-512, 2008.
DOI : 10.1183/09031936.00160307

O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia et al., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002.
DOI : 10.1016/S0735-1097(02)02012-0

URL : https://doi.org/10.1016/s0735-1097(02)02012-0

R. Benza, D. Miller, M. Gomberg-maitland, R. Frantz, A. Foreman et al., Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL), Circulation, vol.122, issue.2, pp.164-172, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.898122

G. Savarese, S. Paolillo, P. Costanzo, D. Amore, C. Cecere et al., Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?, Journal of the American College of Cardiology, vol.60, issue.13, pp.1192-1201, 2012.
DOI : 10.1016/j.jacc.2012.01.083

N. Gabler, B. French, B. Strom, H. Palevsky, D. Taichman et al., Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials, Circulation, vol.126, issue.3, pp.349-356, 2012.
DOI : 10.1161/CIRCULATIONAHA.112.105890

J. Fritz, C. Blair, R. Oudiz, C. Dufton, H. Olschewski et al., Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension, Chest, vol.143, issue.2, pp.315-323, 2013.
DOI : 10.1378/chest.12-0270

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694187/pdf

N. Galie, P. Corris, A. Frost, R. Girgis, J. Granton et al., Updated Treatment Algorithm of Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.62, issue.25, pp.60-72, 2013.
DOI : 10.1016/j.jacc.2013.10.031

P. Herve, M. Humbert, O. Sitbon, F. Parent, H. Nunes et al., PATHOBIOLOGY OF PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.451-458, 2001.
DOI : 10.1016/S0272-5231(05)70283-5

M. Hoeper, M. Sosada, and H. Fabel, Plasma coagulation profiles in patients with severe primary pulmonary hypertension, European Respiratory Journal, vol.12, issue.6, pp.1446-1449, 1998.
DOI : 10.1183/09031936.98.12061446

URL : http://erj.ersjournals.com/content/erj/12/6/1446.full.pdf

K. Huber, R. Beckmann, H. Frank, M. Kneussl, J. Mlczoch et al., Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.150, issue.4, pp.929-933, 1994.
DOI : 10.1164/ajrccm.150.4.7921465

K. Olsson, M. Delcroix, H. Ghofrani, H. Tiede, D. Huscher et al., Anticoagulation and Survival in Pulmonary Arterial HypertensionClinical Perspective, Circulation, vol.129, issue.1, pp.57-65, 2014.
DOI : 10.1161/CIRCULATIONAHA.113.004526

URL : http://circ.ahajournals.org/content/circulationaha/129/1/57.full.pdf

N. Galie, M. Delcroix, A. Ghofrani, P. Jansa, O. Minai et al., Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan, Eur Heart J, vol.35, p.10, 0194.

R. Preston, K. Roberts, D. Miller, N. Hill, and H. Farber, Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)CLINICAL PERSPECTIVE, Circulation, vol.132, issue.25, p.2464, 2014.
DOI : 10.1161/CIRCULATIONAHA.115.018435

J. Cohn, Optimal diuretic therapy for heart failure, The American Journal of Medicine, vol.111, issue.7, p.577, 2001.
DOI : 10.1016/S0002-9343(01)00915-9

S. Rich, M. Seidlitz, E. Dodin, D. Osimani, D. Judd et al., The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension, Chest, vol.114, issue.3, pp.787-792, 1998.
DOI : 10.1378/chest.114.3.787

G. Ruiter, S. Lankhorst, A. Boonstra, P. Postmus, S. Zweegman et al., Iron deficiency is common in idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.37, issue.6, pp.1386-1391, 2011.
DOI : 10.1183/09031936.00100510

URL : http://erj.ersjournals.com/content/erj/37/6/1386.full.pdf

G. Ruiter, I. Lanser, F. De-man, W. Van-der-laarse, J. Wharton et al., Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension, Rheumatology, vol.53, issue.2, pp.285-292, 2014.
DOI : 10.1093/rheumatology/ket331

C. Broberg, B. Bax, D. Okonko, M. Rampling, S. Bayne et al., Blood Viscosity and its Relationship to Iron Deficiency, Symptoms, and Exercise Capacity in Adults With Cyanotic Congenital Heart Disease, Journal of the American College of Cardiology, vol.48, issue.2, pp.356-365, 2006.
DOI : 10.1016/j.jacc.2006.03.040

URL : https://doi.org/10.1016/j.jacc.2006.03.040

C. Rhodes, L. Howard, M. Busbridge, D. Ashby, E. Kondili et al., Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.58, issue.3, pp.300-309, 2011.
DOI : 10.1016/j.jacc.2011.02.057

URL : https://doi.org/10.1016/j.jacc.2011.02.057

A. Van-de-bruaene, M. Delcroix, A. Pasquet, B. De, P. De et al., Iron deficiency is associated with adverse outcome in Eisenmenger patients, European Heart Journal, vol.32, issue.22, pp.2790-2799, 2011.
DOI : 10.1093/eurheartj/ehr130

X. Jaïs, K. Olsson, J. Barbera, I. Blanco, A. Torbicki et al., Pregnancy outcomes in pulmonary arterial hypertension in the modern management era, European Respiratory Journal, vol.40, issue.4, pp.881-885, 2012.
DOI : 10.1183/09031936.00141211

D. Bendayan, M. Hod, G. Oron, A. Sagie, L. Eidelman et al., Pregnancy Outcome in Patients With Pulmonary Arterial Hypertension Receiving Prostacyclin Therapy, Obstetrics & Gynecology, vol.106, issue.5, Part 2, pp.1206-1210, 2005.
DOI : 10.1097/01.AOG.0000164074.64137.f1

M. Bonnin, F. Mercier, O. Sitbon, X. Jaïs, M. Humbert et al., Severe Pulmonary Hypertension during Pregnancy, Anesthesiology, vol.102, issue.6, pp.1133-1137, 2005.
DOI : 10.1097/00000542-200506000-00012

S. Thorne, C. Nelson-piercy, A. Macgregor, S. Gibbs, J. Crowhurst et al., Pregnancy and contraception in heart disease and pulmonary arterial hypertension, Journal of Family Planning and Reproductive Health Care, vol.32, issue.2, pp.75-81, 2006.
DOI : 10.1783/147118906776276486

URL : http://jfprhc.bmj.com/content/familyplanning/32/2/75.full.pdf

E. Weitzenblum, A. Sautegeau, M. Ehrhart, M. Mammosser, and A. Pelletier, Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, vol.131, pp.493-498, 1985.

S. Meyer, V. Mclaughlin, H. Seyfarth, T. Bull, C. Vizza et al., Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey, European Respiratory Journal, vol.41, issue.6, pp.1302-1307, 2013.
DOI : 10.1183/09031936.00089212

E. Weitzenblum, A. Sautegeau, M. Ehrhart, M. Mammosser, and A. Pelletier, Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, vol.131, pp.493-498, 1985.

N. Frydman, J. Steffann, B. Girerd, R. Frydman, A. Munnich et al., mutation: Figure 1???, European Respiratory Journal, vol.39, issue.6, pp.1534-1535, 2012.
DOI : 10.1183/09031936.00185011

L. Guillevin, I. Armstrong, R. Aldrighetti, L. Howard, H. Ryftenius et al., Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives, European Respiratory Review, vol.22, issue.130, pp.535-542, 2013.
DOI : 10.1183/09059180.00005713

. Vivre-avec-l-'htap, Outils de dialogue pour les aidants 197 Rapport de l'OMS-Europe, publié en 1996, Therapeutic Patient Education ? Continuing Education Programmes for Health Care Providers in the field of Chronic Disease, traduit en français en, 1998.